

March 13, 2026

<p>To The Secretary, Listing Department, BSE Limited, 1st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001.</p> <p>Scrip Code: 540975</p>	<p>To The Manager, Listing Department, The National Stock Exchange of India Ltd, Bandra Kurla Complex, Bandra (East), Mumbai 400051.</p> <p>Scrip Symbol: ASTERDM</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir / Madam,

Sub: Intimation regarding the Notice of Postal Ballot

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Postal Ballot Notice along with the explanatory statement ('Postal Ballot Notice') seeking approval of the members of the Company by electronic means on the below mentioned Special Business:

S. No	Particulars
1	Approval for appointment of Dr. Mandayapurath Azad Moopen (DIN:00159403) as Executive Director of the Company
2	Approval for granting loans / giving guarantees or providing securities under Section 185 of the Companies Act, 2013

Please note that in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, Postal Ballot Notice is being sent only in electronic form to all those members, whose names appear in the Register of Members / List of Beneficial Owners as received from National Securities Depository Limited and Central Depository Services (India) Limited, as on Friday, March 06, 2026 ("Cut-off Date").

Information pertaining to E-voting viz. Cut-off date and period of voting are mentioned hereinbelow:

Particulars	Details
Cut-off date for e-voting	Friday, March 6, 2026
E-voting start time and date	From 9:00 am (IST) on Saturday, March 14, 2026
E-voting end time and date	Upto 5:00 pm (IST) on Sunday, April 12, 2026

Aster DM Healthcare Limited - Registered Office

No 7-1-450/20, Plot No-04, Mythri Vihar,
Sanjeev Reddy Nagar, Hyderabad, Ameerpet,
Telangana, India - 500038

Aster DM Healthcare Limited - Corporate Office

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,
Mission Road, Sampangi Rama Nagar, Bengaluru,
Karnataka, India - 560027

Aster

We'll Treat You Well



The Postal Ballot Notice is also available on the Company's website at <https://www.asterdmhealthcare.in/investors/shareholders-services/postal-ballot>

The Voting Results of Postal Ballot will be announced within 2 (two) working days from the conclusion of the remote E-voting i.e., on or before Tuesday, April 14, 2026.

Kindly take the above said information on record.

Thanking you.

Yours faithfully

For **Aster DM Healthcare Limited**

Hemish Purushottam

Company Secretary and Compliance Officer

M. No. A24331

Aster DM Healthcare Limited – Registered Office

No 7-1-450/20, Plot No-04, Mythri Vihar,
Sanjeev Reddy Nagar, Hyderabad, Ameerpet,
Telangana, India - 500038

Aster DM Healthcare Limited – Corporate Office

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,
Mission Road, Sampangi Rama Nagar, Bengaluru,
Karnataka, India - 560027

Aster DM Healthcare Limited

CIN: L85110TS2008PLC207383

Registered office: No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad - 500038, Telangana, India

Corp. office: Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Rd, Rama Nagar, Bangalore-560027, Karnataka, India

Telephone: +91 484 6699999; **Website:** www.asterdmhealthcare.in; **e-mail:** cs@asterdmhealthcare.in

Postal Ballot Notice

(Pursuant to Sections 108 and 110 of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014)

Dear Member(s),

The postal ballot notice ("**Notice**") is hereby given pursuant to Sections 108 and 110 and other applicable provisions, if any, of the Companies Act, 2013 (the "**Act**") read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014, (the "**Rules**"), (including any statutory modification(s) or re-enactments thereof for the time being in force), Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "**SEBI Listing Regulations**"), the Secretarial Standards ("**SS-2**") issued by the Institute of Company Secretaries of India on General Meeting and the relaxations and/or clarifications issued by the Ministry of Corporate Affairs ("**MCA**") vide its General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020 read with subsequent circulars issued from time to time, the latest being General Circular No. 03/2025 dated September 22, 2025 ("**MCA Circulars**"), any circular issued by the Securities and Exchange Board of India ("**SEBI**") and other applicable laws and regulations, if any, for seeking approval of members of Aster DM Healthcare Limited (the "**Company**") via Postal Ballot through remote e-voting only (voting through electronic means) for the resolutions as set out in the notice.

The explanatory statement pursuant to Section 102 of the Act and other applicable provisions of the Act, pertaining to the said resolutions setting out the material facts and the reasons / rationale thereof form part of this postal ballot. The Notice will also be placed on the website of the Company at <https://www.asterdmhealthcare.in/investors/shareholders-services/postal-ballot>, websites of the stock exchanges where the equity shares of the company are listed i.e., BSE Limited ("**BSE**") and National Stock Exchange of India Limited ("**NSE**") at www.bseindia.com and www.nseindia.com respectively and on the website of National Securities Depositories Limited ("**NSDL**") at www.evoting.nsdl.com

In compliance with Regulation 44 of the SEBI Listing Regulations and pursuant to the provisions of Sections 108 and 110 of the Act read with the Rules framed thereunder and the MCA circulars, the manner of voting on the proposed resolution is restricted only to e-voting i.e., by casting votes electronically instead of submitting physical copy of postal ballot forms. Accordingly, the Notice and instructions for e-voting are being sent only through electronic mode to those members whose e-mail address is registered with the Company / Depository Participant(s). The details of the procedure to cast the vote forms part of the 'notes' to this notice.

The Board of Directors of the Company ("**Board**") has appointed Mr. Rajiv Balakrishnan, Director of M/s. Beyond Compliance Corporate Services Private Limited, as the Scrutinizer ("**Scrutinizer**") for conducting the postal ballot / e-voting process in a fair and transparent manner.

The remote e-voting period commences from **Saturday, March 14, 2026 at 9:00 A.M.** (IST) and shall end on **Sunday, April 12, 2026 at 5:00 P.M.** (IST). Members are requested to carefully read the instructions in this postal ballot notice and record their assent (for) or dissent (against) through the remote e-voting process. Remote e-voting will be blocked by NSDL immediately thereafter and will not be allowed beyond the said date and time.

In the event the resolutions as set out in the notice are assented to by the requisite majority by means of remote e-voting, they shall be deemed to have been passed at a general meeting.

SPECIAL BUSINESS:

ITEM NO. 1:

APPROVAL FOR APPOINTMENT OF DR. MANDAYAPURATH AZAD MOOPEN (DIN:00159403) AS EXECUTIVE DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and Schedule V of the Companies Act, 2013 (the **“Act”**), read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, and all other applicable provisions, if any, of the Act, Regulation 17(6)(e) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the **“SEBI Listing Regulations”**) and other applicable provisions of the SEBI Listing Regulations and all other rules, regulations, guidelines of any / various authorities that are or may become applicable (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), enabling provisions of the Articles of Association of the Company, subject to such necessary approval(s), consent(s) or permission(s), as may be required from the Central Government, and based on the recommendation of the Nomination and Remuneration Committee and the approval of the Audit Committee and the Board of Directors, the consent of the members be and is hereby accorded for the appointment of **Dr. Mandayapurath Azad Moopen** (DIN: 00159403), whose current term as Managing Director expires on April 14, 2026, as Executive Director (in whole-time capacity) of the Company for the period from **April 15, 2026 to May 28, 2028**, not liable to retire by rotation, on the following terms of remuneration as previously approved by the shareholders at the annual general meeting on August 29, 2024 as Managing Director and other terms / conditions as may be approved by the Board of Directors from time to time:

- a) Fixed Remuneration:** Consolidated salary of upto INR 10,00,00,000/- (Indian Rupees Ten Crores only) per annum which includes fixed salary and variable pay, allowances and perquisites, with the authority to the Board to fix the salary based on the recommendation of the Nomination and Remuneration Committee within the said maximum limit from time to time including the various components of such salary.
- b) Other benefits / perquisites:** Dr. Mandayapurath Azad Moopen shall be entitled to receive the following perquisites / benefits in accordance with the applicable policy(ies) of the Company:
 - i. Medclaim insurance policy, personal accident policy and term life insurance policy for self; and
 - ii. Chauffeur driven car or any replacement thereof, the entire expenditure of which shall be borne by the Company;

RESOLVED FURTHER THAT in the absence or inadequacy of profits in any financial year during the tenure of Dr. Mandayapurath Azad Moopen, as Executive Director of the Company, Dr. Mandayapurath Azad Moopen, be paid the aforesaid remuneration as minimum remuneration pursuant to Section II of Part II of Schedule V to the Act irrespective of the fact that such remuneration exceeds the limits as prescribed under Section 197 of the Act;

RESOLVED FURTHER THAT the aforementioned remuneration shall be payable notwithstanding that such remuneration may exceed the limits prescribed under Regulation 17(6)(e) of the SEBI Listing Regulations, in any financial year, during the currency of his tenure;

RESOLVED FURTHER THAT in terms of Section 196(3) read with Schedule V to the Act approval be and is hereby accorded for the continuation of and payment of remuneration to Dr. Mandayapurath Azad Moopen as Chairman and Executive Director notwithstanding he attaining the age above 70 years; and

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to do all such acts, deeds and things and execute all such documents, instruments and writings as may be required and to delegate all or any of its powers herein conferred to any Committee of Directors or Director(s) to give effect to the aforesaid resolution.”

ITEM NO. 2:

APPROVAL FOR GRANTING LOANS / GIVING GUARANTEES OR PROVIDING SECURITIES UNDER SECTION 185 OF THE COMPANIES ACT, 2013

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 185 and other applicable provisions, if any, of the Companies Act, 2013 (“**Act**”) and the rules made thereunder, the Memorandum and Articles of Association of the Company and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, the consent of the Members be and is hereby accorded to the Board of Directors (hereinafter referred to as the “**Board**”, which term shall be deemed to include any Committee thereof) to give loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any entity which is a subsidiary or associate or joint venture or group entity of the Company in which any director is deemed to be interested as specified in the explanation to sub-section 2 of Section 185 of the Act up to a sum not exceeding INR 1,500 Crores (Indian Rupees Fifteen Hundred Crores) at any point in time.

RESOLVED FURTHER THAT the aforesaid limit shall be valid for a period of three years from the date of approval of the Members;

RESOLVED FURTHER THAT the aforementioned loan(s) and / or guarantee(s) and / or security(ies) shall only be utilized by the borrower for the purpose of its principal business activities namely those pertaining to its core businesses of hospital services, Pharmacies, and diagnostics; and

RESOLVED FURTHER THAT the Board of Directors (or a Committee thereof constituted for this purpose) be and is hereby authorised to do all such acts, deeds, matters and things including but not limited to authorising signatories, deciding on the timing, manner and extent of carrying out the aforesaid activities and to negotiate, finalise and execute agreement(s) or such other document(s), by whatever name called, and to do all acts, matters and things as may be necessary and to settle any

questions or difficulties that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members and to delegate all or any of the powers or authorities herein conferred to any director(s) or other officer(s) of the Company, and to engage any advisor, consultant, agent or intermediary, as may be deemed necessary.”

By order of the Board of Directors

For **Aster DM Healthcare Limited**

Dr. Mandayapurath Azad Moopen

Chairman

DIN: 00159403

Date: March 10, 2026

Place: Bengaluru

Notes:

1. The Explanatory Statement pursuant to the provisions of Sections 102 and 110 of the Act read with Rule 22 of the Rules setting out material facts concerning each item of business and recommendations of the Board along with rationale on specific items in terms of SEBI Listing Obligations is annexed hereto forms part of this Notice.
2. This Postal Ballot Notice is being sent only by e-mail to the members of the Company, whose names appear on the Register of members / list of Beneficial owners, as received from National Securities Depository Limited (“NSDL”) and Central Depository Services (India) Limited (“CDSL”) on, Friday, March 06, 2026 (the “cut-off date”). Any person who is not a member as on the cut-off date should treat this Postal Ballot Notice for information purposes only. The Postal Ballot Notice is being sent electronically to all the members who have registered their e-mail addresses with the Company / Depositories / Registrar and Share Transfer Agent (“RTA”).

The copy of postal ballot notice may also be downloaded from the weblink: <https://www.asterdmhealthcare.in/investors/shareholders-services/postal-ballot>, the website of NSDL at <https://www.evoting.nsdl.com/>, BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

3. Only those members whose names are appearing in the register of members / list of beneficial owners as on the Cut-Off Date shall be eligible to cast their votes through Postal Ballot. The voting rights of the members shall be in proportion to their share of the paid-up equity share capital of the Company as on the Cut-Off Date. Members can vote for their entire voting rights as per their discretion.
4. As permitted by MCA, vide MCA Circulars, the Company is sending this Notice in electronic form only. Hence, in compliance with the MCA Circulars, hard copy of Notice along with Postal Ballot forms and Pre-paid Business Reply Envelope will not be sent to the members for this Postal Ballot. Accordingly, the members may note that communication of the assent or dissent of the members would take place through the remote e-voting system only.
5. In compliance with the provisions of Section 108, 110 and other applicable provisions of the Act read with Rules 20 and 22 of the Rules and Regulation 44 of the SEBI Listing Regulations, SS-2, the MCA Circulars, the Company has provided only e-voting facility for its members to enable them to cast their votes electronically. For this purpose, the Company has engaged the services of NSDL to provide e-voting facility to its members.

6. The remote e-voting period commences on **Saturday, March 14, 2026 at 09:00 A.M. (IST)** and ends on **Sunday, April 12, 2026 at 05:00 P.M. (IST)**. The e-voting module shall be disabled by NSDL for voting thereafter. Once the members cast the vote on the resolutions, they shall not be allowed to change it subsequently.
7. The last date specified by the Company for e-voting shall be the date on which the resolutions would be deemed to have been passed, if approved by the requisite majority, i.e., **Sunday, April 12, 2026**.
8. The Board of Directors of the Company at its meeting held on January 30, 2026, has appointed Mr. Rajiv Balakrishnan, Director, M/s. Beyond Compliance Corporate Services Private Limited as the Scrutinizer for conducting the postal ballot through e-voting process in a fair and transparent manner and in accordance with the provisions of the Act and the Rules made there under.
9. The Scrutinizer will submit his report to the Chairperson of the Company or to any other person authorized by the Chairman after completion of the scrutiny of the e-voting not later than 2 (two) working days from the last day of e-voting. The Scrutinizer's decision on the validity of votes cast will be final. The result declared along with the Scrutinizer's report shall be communicated to the Stock Exchanges, NSDL and RTA and will also be displayed on the Company's website at <https://www.asterdmhealthcare.in/investors/shareholders-services/postal-ballot> and on notice board of the registered office of the Company.
10. Members holding shares in DEMAT mode, who have not registered their email addresses are requested to register their e-mail addresses with their respective depository participants and members holding shares in physical mode are requested to update their e-mail addresses with the Company by sending an email to cs@asterdmhealthcare.in to receive the Notice in electronic mode. The Members may follow the process detailed below for registration of e-mail ID to obtain the Notice, user ID / password for e-voting:

Type of Holder	Registering Email Address	
Physical	Send a request to the Company at cs@asterdmhealthcare.in providing Folio No., Name of the member, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (Self attested scanned copy of Aadhar card) for registering e-mail address.	
	Form for availing investor services to register PAN, email address, bank details and other KYC details or changes / update thereof for securities held in physical mode	Form ISR - 1
DEMAT	Please contact your DP and register your email address in your demat account, as per the process advised by your DP.	

Alternatively, member may send an e-mail request to evoting@nsdl.com for obtaining User ID and Password for e-voting. After successful submission of the e-mail address, NSDL will e-mail a copy of this Notice along with the remote e-voting user ID and password, within 48 hours of successful registration of the e-mail address by the member. In case of any queries, members may write to evoting@nsdl.com.

11. All material documents referred to in the explanatory statement will be available for inspection at the Registered Office of the Company during office hours on all working days from the date of dispatch until the last date for receipt of votes by e-voting. Alternately, members may also send their requests to cs@asterdmhealthcare.in or evoting@nsdl.com from their registered e-mail address mentioning their names, folio numbers, DP ID and Client ID during the voting period of the postal ballot.
12. Contact details of the person responsible to address the queries / grievances connected with the voting by electronic means, if any:

Mr. Hemish Purushottam,
Company Secretary and Compliance Officer,
Aster DM Healthcare Limited,
Corporate office: Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,
Mission Road, Sampangi Rama Nagar,
Bangalore - 560027, Karnataka, India
e-mail ID: cs@asterdmhealthcare.in

EXPLANATORY STATEMENT PURSUANT TO SECTIONS 102 AND 110 OF THE ACT

ITEM NO. 1

The shareholders of the Company, at their 14th Annual General Meeting (“AGM”) held on August 25, 2022, approved the re-appointment of Dr. Mandayapurath Azad Moopen (“**Dr. Azad Moopen**”) as Managing Director of the Company for a further period of three (3) years, subject to the approval of the Central Government in accordance with Section 196 read with Schedule V and other applicable provisions of the Companies Act, 2013 (“**Act**”). Accordingly, his current tenure as Managing Director will conclude on April 14, 2026.

Further, the shareholders of the Company, at their 16th AGM held on August 29, 2024, approved the revision of the consolidated remuneration payable to Dr. Azad Moopen to up to INR 10,00,00,000 (Indian Rupees Ten Crores only) per annum, with effect from April 1, 2024, until the completion of his current tenure. This remuneration is in addition to other benefits such as the use of the Company’s car, chauffeur and telephone for official purposes, gratuity, and leave encashment in accordance with the rules of the Company, as detailed in the said AGM notice.

The members may note that pursuant to the Shareholders’ Agreement dated November 29, 2024 entered into amongst the Company, the Aster Promoters and BCP Asia II Topco IV Pte. Ltd. (as defined therein), in connection with the ongoing amalgamation of Quality Care India Limited (“**QCIL**”) with the Company, Dr. Azad Moopen shall continue to serve as the Executive Chairperson of the Company for a period of three (3) years and six (6) months from the date of the said agreement (i.e., upto May 28, 2028) and, thereafter, as Non-Executive Chairperson. It may be noted that the Company has received an overwhelming 96.68% voting approval from shareholders, along with a significant majority of minority shareholders and creditors, voting in favour of the proposed scheme of amalgamation.

In view of completion of his current tenure as Managing Director and to align with the proposed changes in the organizational structure of the Company pursuant to the amalgamation, it is proposed to redesignate Dr. Azad Moopen from his existing position as Chairman and Managing Director to Chairman and Executive Director of the Company.

Accordingly, subject to the approval of the shareholders of the Company and relevant regulatory authority (as required), the Board of Directors, based on the recommendations of the Nomination and Remuneration Committee (“**NRC**”), at their respective meetings held on March 10, 2026, and March 04, 2026 has, *inter alia*:

- a. approved the redesignation of Dr. Azad Moopen from Chairman and Managing Director to Chairman and Executive Director of the Company, with effect from April 15, 2026;
- b. approved his appointment as Executive Director for a further term a period commencing from April 15, 2026, up to May 28, 2028 (both days inclusive), not liable to retire by rotation;
- c. approved the remuneration payable to him and the terms and conditions thereof, including payment of minimum remuneration in the event of absence or inadequacy of profits; and
- d. recommended to the shareholders the continuation of his office and payment of remuneration notwithstanding that he has attained and will continue to hold office after attaining the age of seventy (70) years, in accordance with the provisions of Section 196(3) read with Schedule V and other applicable provisions of the Act.

Further, in accordance with Regulation 23 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as well as the relevant provisions of the Act, the Audit Committee, through the approval of the Independent Directors at its meeting held on March 10, 2026, has pre-approved the remuneration proposed to be paid to Dr. Azad Moopen, being a related party transaction.

In terms of Section 196 of the Act read with Schedule V to the Act, approval of shareholders by way of a Special Resolution is required for the appointment or continuation of employment of a person as Whole-time Director if such person has attained the age of 70 years, and the explanatory statement must set out the justification for such appointment. Accordingly, a Special Resolution is proposed for the appointment of Dr. Azad Moopen, aged 72 years, as Executive Director of the Company.

The Audit Committee (through the approval of the independent directors), NRC and the Board of Directors (of which atleast one-half comprises Independent Directors) considered, inter-alia, the following while approving the above matters:

- (i) Dr. Azad Moopen, having founded the Company, has been associated as a director, since its establishment. His vision has played a pivotal role in transforming a single-doctor clinic established in Dubai in 1987, into a leading global healthcare organization.
- (ii) Dr. Azad Moopen brings with him decades of institutional knowledge, operational expertise, and industry leadership that are integral to the Company's long-term success. He has been instrumental in establishing the Company's strategic vision, operational framework, and market positioning, and is widely respected among investors, healthcare professionals, employees, and other key stakeholders as a figure synonymous with stability and confidence in the Company's future. His continued involvement is not merely a function of his shareholding, it reflects the immense value he contributes as a leader and the critical role he plays in maintaining stakeholder trust, organizational cohesion, and the long-term sustainability of both the Company and its broader community of doctors and employees.
- (iii) Under Dr. Azad Moopen's leadership, the Company has expanded to more than five hundred healthcare facilities operating across seven countries viz., United Arab Emirates (UAE), Kingdom of Saudi Arabia (KSA), Oman, Qatar, Jordan, Bahrain, Cayman Islands (Collectively called Gulf Cooperation Council (GCC)), Mauritius and India, offering a comprehensive spectrum of medical services and touching millions of lives each year.
- (iv) In addition, the Company (on a consolidated basis) has demonstrated robust growth under Dr. Azad Moopen's guidance, as summarized below:

Financial performance

FY	Operating Revenue (INR in crores)	Operating EBITDA (INR in crores)	Operating EBITDA margin (in %)	PAT (Post NCI) (INR in crores)	PAT margin (in %)	Market capitalization (INR in crores)	*ROCE (in %)
25	4,138	806	19	307	7	24,067	20
24	3,699	620	17	188	5	20,357	16
23	2,983	477	16	147	5	11,970	13
22	2,384	353	15	60	3	9,819	10
21	1,654	144	9	(91)	0	6,826	1

* ROCE= EBIT / Average Capital Employed; Capital employed excludes CWIP & Land Revaluation reserve

Operational performance

FY	Bed Capacity (in nos.)	Occupancy Rates (in %)	ARPOB (in INR)
25	5,159	65	45,000
24	4,867	68	40,100
23	4,317	68	36,500
22	3,905	66	33,500
21	3,757	56	30,100

- (v) There has been no increase in Dr. Azad Moopen's remuneration since 2024. Also, Dr. Azad Moopen doesn't receive any remuneration from any of the group companies in India or abroad.

The Audit Committee, NRC and the Board also considered the proposed amalgamation of QCIL with the Company, which will lead to a significant increase in the scale, geographic presence, and operational footprint of the Company.

It was noted that while Dr. Azad Moopen has completed 72 years of age, and will be taking on a Non-Executive Chairperson's role post his proposed term as the executive director, designated as the Chairman of the Company, the increase in the scale and operations of the merged entity in the next 3-5 years necessitates Dr. Azad Moopen to take on an expanded role in providing strategic direction to the Company and guidance to the Board, along with being closely involved in executive leadership. Further, the transitional nature of Dr. Azad Moopen's designation on account of this transaction is by design to preserve a degree of continuity and strategic coherence in leadership, particularly in a period of significant corporate transition, with the intent to navigate the challenges as mentioned above during the initial merger integration phase and thereafter handing the day-to-day management to the Company's professional leadership team while continuing to provide strategic guidance. Specifically, in relation to Dr. Azad Moopen's proposed concurrent appointment as an Executive Director and Chairman, it was noted that there is no legal prohibition restricting Dr. Azad Moopen from holding such a combined position, and that Dr. Azad Moopen is already serving as the Executive Chairman & Managing Director of the Company. The dual role of Executive Chairman reflects a considered and deliberate decision tailored to the Company's specific circumstances on account of the proposed merger (i.e. a Company which will be one of the top 3 hospital chains in India).

A transaction of this scale and complexity demands experienced and consistent leadership to navigate the operational, regulatory, and cultural challenges that inevitably accompany a major corporate consolidation. Appointing an experienced and trusted Executive Chairman for a defined transitional period is a prudent governance choice, one that protects the interests of all stakeholders by providing a stable foundation from which the combined entity can grow. This arrangement represents a thoughtful and measured approach to ensuring that the Company's long-term strategic direction remains in capable hands during what is unquestionably a transformative and sensitive period for the organization.

Considering Dr. Azad Moopen's extensive contributions, deep expertise in the healthcare sector, proven leadership capabilities, and after evaluation of his performance, and keeping in view the anticipated changes in the landscape of the Company and the Group owing to the merger, and based on the recommendations of the Audit Committee and the NRC, the Board has approved and proposes the appointment of Dr. Azad Moopen as Executive Director of the Company for a period, commencing from April 15, 2026 and ending on May 28, 2028, on the terms and conditions as set out herein.

The Board also seeks the approval of the members of the Company for the payment of remuneration, to Dr. Azad Moopen, which shall be valid and payable with effect from April 15, 2026 and until May 28, 2028, in the event that the Company has no profits or has inadequate profits, calculated under Section 198 of the Act in any financial year during his tenure, with the Board having the authority to vary such terms within the overall limits as prescribed under applicable laws or as approved by the shareholders in accordance with applicable laws, as applicable.

The details as required under Section II of Part II of Schedule V of the Act along with those required under Paragraph 1.2.5. of Secretarial Standard on General Meeting (SS-2) issued by the Institute of Company Secretaries of India and under Regulation 36(3) of SEBI Listing Regulations are given below:

1. General information:

- a. Nature of industry: The Company is in the business of providing Healthcare services.
- b. Date or expected date of commencement of commercial production: Not applicable.
- c. In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus: Not applicable
- d. Financial performance based on given indicators:

(INR in Crores)

Particulars	2024-25	2023-24	2022-23
Total Income	8,059.15	2,085.52	1,583.51
Total Expenditure	2,094.05	1,876.17	1,401.18
Profit / (Loss) before exceptional items and tax	5,965.10	209.35	182.33
Profit/(Loss) before tax	6,288.25	209.35	182.33
Profit for the year	6,208.97	156.96	173.29
Total other comprehensive income	6,207.94	156.32	173.70
Net worth	3,285.67	2,863.19	3,060.39

- e. Foreign investments or collaborations, if any: As on December 31, 2025, around 69% of the paid-up equity share capital of the Company is held by foreign companies and foreign individuals, foreign portfolio investors, foreign venture capital investors and non-resident Indians.

2. Information about the appointee

Name of the Director	Dr. Mandayapurath Azad Moopen
Age (in years)	72 years
Director Identification Number ("DIN")	00159403
Father's name	Mr. Ahmed Unni Moopan
Date of Birth	April 15, 1953
Brief Profile (Educational Qualifications & Experience)	<p>Dr. Azad Moopen, the visionary Founder Chairman of the Company, has been the Director of the Company since its inception. He is a Gold Medallist in MBBS and a Post-Graduate in General Medicine from Calicut Government Medical College in Kerala, and a Diploma holder in Chest Diseases from Delhi University, India. He has been responsible for the Company's overall business operations and for setting forth the group strategy and vision.</p> <p>Dr. Azad Moopen's contribution to the development of the healthcare sector has been exceptional. Commencing with a single-doctor clinic established in Dubai in 1987, he has, over the past four decades, led the transformation of Aster DM Healthcare into a global healthcare organization.</p>

Nature of expertise	Healthcare, Finance, Accountancy & Audit, Law, Technology, Risk Management, Strategy & Marketing, Board & Governance, Global Business and Leadership.												
Job Profile and his suitability	As Executive Chairman, Dr. Azad Moopen will lead the Company's strategic direction and provide mentorship on clinical governance, drive the successful integration of the acquired QCIL hospitals into Aster's network, and oversee key initiatives in digital health and quality improvement, while continuing to guide the Board on corporate governance and long-term strategy.												
Recognition / Awards	<p>Some of the accolades of Dr. Azad Moopen, include:</p> <ul style="list-style-type: none"> • 2009 – Best Doctor Award, Government of Kerala • 2010 – Pravasi Bharatiya Samman, Government of India • 2011 – Padma Shri, Government of India • 2018 – Lifetime Achievement Award, FICCI Healthcare Excellence Awards • 2019 – Visionary CEO of the Year, CEO Middle East Awards • 2019 – Fellowship of the Royal College of Physicians (FRCP), UK • 2021 – Harvard Business Council Award for Organizational Excellence • 2021 – Appointment to the Advisory Council of Dubai International Chamber • 2025 – 'Healthcare Icon of the year' at Economic Times Healthcare Awards 2025 • 2025 – 'Lifetime Achievement Award' by Entrepreneur India 2025 • 2025 – 'Legend in the Healthcare Industry' at FICCI Heal • 2025 – 'Top 5 Healthcare Leaders 2025' by Forbes Middle East • 2026 – Lifetime Achievement Award, conferred by Mount Judi Ventures for transformative impact on the global healthcare landscape. 												
Date of first appointment on the board	January 18, 2008												
Terms and Conditions of appointment	Appointment as Executive Director for the period April 15, 2026 to May 28, 2028, not liable to retire by rotation.												
Past remuneration	During the FY 2024-25, Dr. Azad Moopen drew a remuneration of INR 9.50 crore from the Company.												
Remuneration Proposed	Refer the resolution for more details.												
Comparative remuneration profile with respect to the industry	<p>Market Compensation Benchmarking:</p> <p>The Company has undertaken a comparative analysis of market compensation across leading companies in the hospital, Pharmacies, and diagnostic chains. The summary of such benchmarking is provided below:</p> <p style="text-align: right;">(INR in crores)</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Annual Compensation (includes Fixed, Variable pay & other perquisites)</th> <th>25th %</th> <th>Median</th> <th>75th %</th> <th>Maximum</th> <th>Average</th> </tr> </thead> <tbody> <tr> <td></td> <td style="text-align: center;">6.18</td> <td style="text-align: center;">10.55</td> <td style="text-align: center;">18.56</td> <td style="text-align: center;">29.50</td> <td style="text-align: center;">13.34</td> </tr> </tbody> </table>	Annual Compensation (includes Fixed, Variable pay & other perquisites)	25 th %	Median	75 th %	Maximum	Average		6.18	10.55	18.56	29.50	13.34
Annual Compensation (includes Fixed, Variable pay & other perquisites)	25 th %	Median	75 th %	Maximum	Average								
	6.18	10.55	18.56	29.50	13.34								

Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel or other director, if any	Apart from receiving remuneration and corporate action related benefits in his capacity as a shareholder of the Company, he does not have any other pecuniary relationship with the Company, its managerial personnel, or other Directors, except that Ms. Alisha Moopen (Deputy Managing Director) and Dr. Zeba Azad Moopen (Non-Executive Director) are the daughters of Dr. Azad Moopen.
Directorship in other Companies (including listed entities)	1. M/s. Malabar Institute of Medical Sciences Ltd. 2. M/s. Wayanad Infrastructure Private Limited 3. M/s. Norka-Roots (a Company under Section 8 of the Act)
Committee Memberships in other Boards (only Audit Committee and Stakeholders' Relationship Committee)	NIL
Listed entities from which Director has resigned in the past three years	NIL
Number of meetings of the Board attended during the year (as on 10 March 2026)	Out of eight meetings held during the period, Dr. Azad Moopen attended all the meetings
Number of equity shares held (including joint holdings, if any)	14,70,676
Number of equity shares held as a beneficial owner	18,68,53,810 (36.06% as a beneficiary through Union Investment Pvt. Ltd.

3. Other Information:

- a. Reasons of loss or inadequate profits: Not applicable.
- b. Steps taken or proposed to be taken for improvement: Not applicable.
- c. Expected increase in productivity and profit in measurable terms: Not applicable.

The Company is presently profitable and, based on prevailing micro and macroeconomic conditions, does not foresee a situation of loss or inadequacy of profits. However, as a matter of abundant caution and to ensure compliance with the provisions of Section 197 read with Schedule V of the Act, approval of the Members is being sought for payment of the aforesaid remuneration as minimum remuneration pursuant to Section II of Part II of Schedule V to the Act, in the event of loss or inadequacy of profits, notwithstanding that such remuneration may exceed the limits specified under Section 197 of the Act.

4. Other disclosures:

- a. The above may be treated as written memorandum setting out the terms of appointment of Whole-time Director pursuant to Section 190(1)(b) of the Act.
- b. The Company has not made any default in repayment of its debt or interest payable thereon during the preceding FY 2024-25. Dr. Azad Moopen is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
- c. As Dr. Azad Moopen is a Non-Resident Indian, his appointment as an Executive Director is subject to such approvals, as may be required under the applicable provisions of the Act, including approval of the Central Government, if applicable. He satisfies all other conditions prescribed under Schedule V to the Act.
- d. The Company has received all statutory disclosures / declarations from Dr. Azad Moopen as required under the Act and other applicable laws.

Dr. Azad Moopen is interested in the resolution as it relates to his own appointment and remuneration. Except Ms. Alisha Moopen (Deputy Managing Director) and Dr. Zeba Azad Moopen (Non-Executive Director) who are his daughters, none of the other Directors and Key Managerial Personnel of the Company and their relatives are concerned or interested, financial or otherwise in this resolution, except to the extent of their shareholding, if any, in the Company.

The Board of Directors recommends the special resolution as set out at item no. 1 of this notice for your approval.

ITEM NO.2: APPROVAL FOR GRANTING LOANS / GIVING GUARANTEES OR PROVIDING SECURITIES UNDER SECTION 185 OF THE COMPANIES ACT, 2013

The members may note that in terms of Section 185(1) of the Act, a company is prohibited from advancing any loan, including any loan represented by a book debt, or giving any guarantee, or providing any security in connection with any loan taken by any director of the company or any other person in whom the director is interested.

However, as per Section 185(2) of the Act, a company may, by passing a Special Resolution, extend any loan, guarantee or security to any person in whom any of its directors is interested, subject to the following conditions:

- the loans are utilized by the borrowing company for its principal business activities; and
- the company granting such loan or providing such guarantee / security has obtained prior approval of its members by a special resolution.

The Members may further note that the Company's businesses are carried out through various subsidiaries, joint ventures, associates and other companies within the Aster DM group of companies, which operate in its core businesses of hospital services, pharmacies and diagnostics ("Group Companies").

From time to time, the Group Companies may require financial support in the form of loans, guarantees or securities to meet their working capital requirements, capital expenditure for new projects, or other expenditures in connection with their principal business activities.

Accordingly, in order to enable the Company to provide timely financial support to the Group Companies, approval of the Members is sought to authorize the Board of Directors to grant loans or give guarantees or provide securities in connection with the loans availed by such Group Companies, from time to time, within an overall limit of INR 1,500 Crore (Indian Rupees One Thousand Five Hundred Crore only).

The quantum of financial assistance, utilization of funds, tenure of the loan and other related terms for the Group Companies shall be evaluated on a case-by-case basis and approved by the Board of Directors of the Company (or any Committee thereof), including the Audit Committee, in accordance with the applicable provisions of the Act. Such evaluation shall ensure that the financial assistance is extended on arm's length terms and that the funds are utilized strictly for the principal business activities of the borrowing entity.

Further, the Audit Committee of the Board shall review and monitor such financial assistance on a periodic basis to ensure compliance with the approved terms and applicable regulatory requirements.

The aforesaid limit shall be valid for a period of three years from the date of approval of the Members.

Any such financial assistance shall be extended on commercial terms, including interest rate, tenure and security, consistent with prevailing market conditions and commensurate with the credit risk of the borrowing entity. The interest rate or fee charged shall not be more favourable to the borrowing entity than the terms on which the Company could obtain similar financing for comparable risk.

Accordingly, the approval of the Members is sought by way of a Special Resolution under Section 185(2) and other applicable provisions of the Act, authorizing the Board of Directors of the Company (which term shall be deemed to include any Committee thereof) to grant loans or give guarantees or provide securities in connection with the loans taken by Group Companies, as may be considered necessary from time to time, subject to such terms and conditions as the Board may deem fit and proper in the interest of the Company.

The Board recommends the Resolution at Item No. 2 for approval of the Members as a Special Resolution.

None of the Directors or Key Managerial Personnel of the Company, or their relatives, are in any way concerned or interested in the Resolution, except to the extent of their directorships or shareholding, if any, in the Group Companies to which such financial assistance may be extended.

E-VOTING INSTRUCTIONS

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> 1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 2. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

	<p>5. Shareholders / Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.</p> <p style="text-align: center;">NSDL Mobile App is available on</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p> </div> <div style="text-align: center;">  <p>Google Play</p> </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 10px;">   </div>
<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<ol style="list-style-type: none"> 1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers’ website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
<p>Individual Shareholders (holding securities in demat mode) login through their depository participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

(ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered**

6. If you are unable to retrieve or have not received the “Initial password” or have forgotten your password:
 - a) Click on “**Forgot User Details/Password?**”(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) **Physical User Reset Password?**” (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to cosec@beyondcompliance.in with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "**Upload Board Resolution / Authority Letter**" displayed under "**e-Voting**" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?” option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on: 022 - 4886 7000 or send a request to Mr. Falguni Chakrobarty, Assistant Manager at evoting@nsdl.com

Process for those shareholders whose email IDs are not registered with the depositories for procuring user id and password and registration of e mail IDs for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to cs@asterdmhealthcare.in.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to cs@asterdmhealthcare.in. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. **Login method for e-Voting for Individual shareholders holding securities in demat mode**.
3. Alternatively, shareholders / members may send a request to evoting@nsdl.com for procuring user ID and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.